Skip to main content
Dryad logo

Data from: Prognostic relevance of cortical superficial siderosis in cerebral amyloid angiopathy

Citation

Wollenweber, Frank Arne et al. (2019), Data from: Prognostic relevance of cortical superficial siderosis in cerebral amyloid angiopathy, Dryad, Dataset, https://doi.org/10.5061/dryad.rb9665d

Abstract

Objective: To investigate the prognostic relevance of cortical superficial siderosis (cSS) in patients with cerebral amyloid angiopathy (CAA). Methods: 302 patients fulfilling the modified Boston criteria for probable or possible CAA were enrolled into a prospective, multicenter cohort study and followed for 12 months. cSS was assessed on T2*/SWI MRI. The predefined primary composite endpoint was incident stroke or death in patients with cSS compared to those without. Secondary analyses included cerebrovascular events and functional outcome measured by the modified Rankin scale (mRS). Multiple regression analysis was performed to adjust for possible confounders.1 Results: cSS prevalence was 40%. The primary endpoint occurred more frequently in patients with cSS (22%, 27/121) compared to those without (8%, 15/181, p=0.001). Rates of CAA-related incident intracranial hemorrhage were 17% (cSS) and 4% (no cSS, p=0.0003). The proportion of patients being functionally independent (mRS 0-2) 12 months from baseline were 59% (cSS) and 82% (no cSS), p=0.00002). Presence of cSS was associated with the primary endpoint (adjusted odds ratio [OR] 1.2, 95% CI 1.1-1.3, p=0.0005), incident intracranial hemorrhage (adjusted OR 1.2, 95% CI 1.1-1.3, p=0.0003) and less favorable outcome as assessed by the mRS (common OR, 1.9, 95% CI 1.2-3.1, p=0.009). Similar results were obtained in analyses restricted to patients with probable CAA and to patients with disseminated cSS (all p<0.005). Conclusions: Patients with cSS and suspected CAA are at high risk for CAA-related incident intracranial hemorrhage and poor functional outcome. Both the presence and extent of cSS have prognostic relevance and may influence clinical decision making.

Usage Notes

Location

Europe